Remote Ischaemic Preconditioning in Childhood Cancer
NCT03166813 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68
Last updated 2022-06-08
Summary
Survival rates of children with cancers have improved significantly in the recent few decades. Nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern. Exploration of new strategies to protect the heart in the long term is therefore of paramount importance in children undergoing treatment of cancers. Previous cardioprotective interventions hav focused on changing the formulation or rate of administration of anthracyclines but with no observable benefits. While dexrazoxane, an iron chelator, has shown to reduce cardiotoxic outcomes, there remains worries of an association between dexrazoxane use and an increased risk of developing secondary malignancies. Recently, the clinical application of remote ischaemic preconditioning (RIPC) as a non-invasive and an easily applicable non-pharmacological myocardial protective intervention has gained increasing interest. Remote ischaemic preconditioning is the phenomenon in which brief episodes of reversible ischaemia and reperfusion applied to one vascular bed render resistance to ischaemia reperfusion injury of tissues and organs distant away. It can be achieved by repeated 5-minute cycles of inflation and deflation of blood pressure cuff placed over the arm or leg to induce limb ischaemia and reperfusion injury. It is noteworthy that anthracycline cardiotoxicity and myocardial reperfusion injury occur through similar pathways. Hence, the investigators hypothesize that RIPC may reduce myocardial injury in children receiving anthracycline chemotherapy for childhood malignancies. The proposed study aims to conduct a parallel-group blinded randomized controlled trial study to investigate whether RIPC may reduce heart damage in childhood cancer patients undergoing anthracycline-based treatment, and to determine the effect of RIPC on the changes in levels of cardiac troponin T, and on the occurrence of clinical cardiovascular events and echocardiographic indices.
Conditions
Interventions
- PROCEDURE
-
Remote Ischaemic Preconditioning
The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
- OTHER
-
Control
Placement of blood pressure cuff without inflation for 30 minutes.
Sponsors & Collaborators
-
The University of Hong Kong
lead OTHER
Principal Investigators
-
Yiu-fai Cheung, MD · The University of Hong Kong
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 4 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-01
- Primary Completion
- 2022-06-01
- Completion
- 2022-06-01
Countries
- Hong Kong
Study Locations
More Related Trials
-
Role of Tumoral Biomarker B3 Adrenergic Receptor in Paediatric Solid Tumours
NCT06312150 ·Status: RECRUITING ·Phase: NA
-
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
NCT00016861 ·Status: COMPLETED ·Phase: PHASE1
-
DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors
NCT04213612 ·Status: UNKNOWN ·Phase: PHASE1
-
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
NCT00003070 ·Status: COMPLETED ·Phase: PHASE3
-
Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors
NCT00313521 ·Status: UNKNOWN ·Phase: PHASE2
-
Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity
NCT04036045 ·Status: WITHDRAWN
-
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
NCT00346164 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03126916 ·Status: RECRUITING ·Phase: PHASE3
-
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
NCT00165139 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
NCT07168980 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
NCT00302003 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
NCT00416832 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma
NCT00276731 ·Status: UNKNOWN ·Phase: PHASE3
-
Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia
NCT02764398 ·Status: COMPLETED
-
Study of Irinotecan on a Weekly Schedule in Children
NCT00062842 ·Status: COMPLETED ·Phase: PHASE1
-
Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
NCT05602103 ·Status: NOT_YET_RECRUITING
-
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
NCT00004010 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
NCT00057811 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer
NCT00897871 ·Status: UNKNOWN
-
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
NCT00003423 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
NCT01026220 ·Status: COMPLETED ·Phase: PHASE3
-
PRecISion Medicine for Children With Cancer
NCT03336931 ·Status: ACTIVE_NOT_RECRUITING
-
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
NCT03420963 ·Status: TERMINATED ·Phase: PHASE1
-
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
NCT00024284 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
NCT05302921 ·Status: COMPLETED ·Phase: PHASE2